08th week of 2015 patent applcation highlights part 42 |
Patent application number | Title | Published |
20150051191 | TREATMENT OF ALCOHOLISM USING IBUDILAST - Alcoholism, and symptoms and negative effects thereof may be treated using ibudilast or a pharmaceutically acceptable salt thereof. Abstinence from alcohol consumption may be maintained using ibudilast or a pharmaceutically acceptable salt thereof. Withdrawal from alcohol may be facilitated and negative effects thereof reduced by using ibudilast or a pharmaceutically acceptable salt thereof. | 2015-02-19 |
20150051192 | BLOCKING OF CUE-INDUCED DRUG REINSTATEMENT - A method of preventing drug use relapse by administering an effective amount of an α3β4 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use. A method of preventing drug use relapse due to cue inducement by administering an effective amount of an α3β4 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use during cue inducement. A method of preventing drug use relapse due to cue inducement by modulating the dopaminergic mesolimbic pathway by blocking α3β4 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala of a mammal after an initial period of drug use, and preventing a relapse of drug use during cue inducement. A method of preventing drug use relapse by preventing a relapse of drug use during cue inducement. | 2015-02-19 |
20150051193 | PI-kinase Inhibitors with Broad Spectrum Anti-Infective Activity - Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like. | 2015-02-19 |
20150051195 | NOVEL VIRAL REPLICATION INHIBITORS - The present invention relates to a series of novel compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having antiviral activity. | 2015-02-19 |
20150051196 | INHIBITORS OF C-FMS KINASE - The invention is directed to compounds of Formula I: | 2015-02-19 |
20150051197 | HETEROCYCLIC COMPOUND AND USE THEREOF - Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD) and the like. The compound represented by formula (I): | 2015-02-19 |
20150051198 | Highly Concentrated Stable Meloxicam Solutions for Needleless Injection - An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients. | 2015-02-19 |
20150051199 | PHARMACEUTICAL COMPOUNDS - The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): | 2015-02-19 |
20150051200 | GUM RESIN AS A CARRIER FOR TOPICAL APPLICATION OF PHARMACOLOGICALLY ACTIVE AGENTS - Described are pharmacological compositions comprising a gum resin; a pharmacologically active agent and a topically acceptable volatile solvent for the gum resin and active agent. Also described are methods for the transdermal or transmucosal delivery of a pharmacologically active agent using such compositions. | 2015-02-19 |
20150051201 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS - Compounds of formula I: | 2015-02-19 |
20150051202 | TRIAZOLOPYRAZINE DERIVATIVES - Compounds of the formula I | 2015-02-19 |
20150051203 | TRIAZOLE DERIVATIVES AS HSP90 INHIBITORS - A compound of structural formula (I) or (II): as HSP90 inhibitors that possess significantly improved bioavailability over comparative compounds, which are suitable for the treatment of hyperproliferative diseases such as cancer, infections, immune disorders, inflammation, and CNS related disorders. | 2015-02-19 |
20150051204 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME - Present invention refers to new compounds of formula I or II, its synthesis and its use in the treatment of metabolic syndrome, particularly for the treatment of type I or type II diabetes and/or metabolic syndrome or metabolic disease or metabolic disorders. | 2015-02-19 |
20150051205 | SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS - Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidase and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplasatic agents or glucuronidase-substrate agents or compounds. | 2015-02-19 |
20150051206 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS - The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases. | 2015-02-19 |
20150051207 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER - The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. The invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases. | 2015-02-19 |
20150051208 | PYRIDINONES - The present invention encompasses compounds of general formula (I) | 2015-02-19 |
20150051209 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK - The present invention relates to compounds of formula I: | 2015-02-19 |
20150051210 | Tyrosine Kinase Inhibitor Combinations and their Use - The invention relates to pharmaceutical combination product comprising (i) a MET inhibitor and (ii) an FGFR inhibitor, or a pharmaceutical acceptable salt thereof, respectively, or a prodrug thereof, respectively, and at least one pharmaceutically acceptable carrier. | 2015-02-19 |
20150051211 | POLY (ADP-RIBOSE) POLYMERASE INHIBITOR - Disclosed are a phthalic hydrazide (phthalazine ketone) compound, and a pharmaceutical composition comprising the same. As a DNA repair enzyme poly (ADP-ribozyme) polymerase inhibitor, the compound and the pharmaceutical composition can effectively treat diseases involving PARP enzymatic activity, including cancer, neural degenerative diseases, inflammation and the like. | 2015-02-19 |
20150051212 | Compositions And Methods For Inhibiting Drusen - Described herein are methods for inhibiting drusen. | 2015-02-19 |
20150051213 | NOVEL SALTS OF SITAGLIPTIN - The present invention provides sitagliptin 4-methylsalicylate, sitagliptin myristate, sitagliptin isophthalate, sitagliptin isonicotinide, sitagliptin adipate, their polymorphic form, processes for their preparation and pharmaceutical compositions thereof. | 2015-02-19 |
20150051214 | LIVER X RECEPTOR MODULATORS - Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described. | 2015-02-19 |
20150051215 | PI3K INHIBITORS FOR TREATING FIBROTIC DISEASES - The present invention is directed to compounds or pharmaceutically acceptable salts thereof for use in the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). | 2015-02-19 |
20150051216 | ORAL SPRAY FORMULATIONS AND METHODS FOR ADMINISTRATION OF SILDENAFIL - The present disclosure is directed to chemically-stable and pharmaceutically acceptable sildenafil oral spray formulations for the treatment of diseases such as pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction, wherein the oral spray formulation has a pH of about 1.5 to less than 3.0. The present disclosure is also directed to methods for treating diseases such as pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction. | 2015-02-19 |
20150051217 | HYDROXYLATED PYRIMIDYL CYCLOPENTANE AS AKT PROTEIN KINASE INHIBITOR - The present invention provides a compound and pharmaceutically acceptable salts thereof, comprising the Formula I: | 2015-02-19 |
20150051218 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES - This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2015-02-19 |
20150051219 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS - A method of treating exposure to organophosphate agents through the use of compounds comprising tetrahydroindolone and arylpiperazine moieties. | 2015-02-19 |
20150051220 | COMPOUNDS FOR USE IN THERAPY - A compound of formula (I) | 2015-02-19 |
20150051222 | PROCESS FOR THE PREPARATION OF N-[5-(3,5-DIFLUORO-BENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2- -(TETRAHYDRO-PYRAN-4-YLAMINO)-BENZAMIDE - The present invention relates to a process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide. Novel solid forms of this compound, their utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing them are also object of the present invention. | 2015-02-19 |
20150051223 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM - The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: | 2015-02-19 |
20150051224 | THERAPEUTIC METHODS AND COMPOUNDS - The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation. | 2015-02-19 |
20150051225 | SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: | 2015-02-19 |
20150051226 | 4,4-DIFLUORO-PIPERIDINE-COMPOUNDS - The invention, in a first aspect relates to compounds of formula (I) | 2015-02-19 |
20150051227 | PREDICTIVE BIOMARKER USEFUL FOR CANCER THERAPY MEDIATED BY A CDK INHIBITOR - The present invention provides a predictive biomarker whose expression level is useful for identifying patients responsive to a therapeutically effective dose of a CDK inhibitor. In one embodiment of the invention, the predictive biomarker is the ratio of MCL-1 to BCL-xL (MCL-1:BCL-xL ratio) and the CDK inhibitor is SCH 927965 (Dinaciclib). | 2015-02-19 |
20150051228 | AMORPHOUS FORM OF LINAGLIPTIN AND PROCESS FOR PREPARATION THEREOF - The present invention relates to an amorphous form of linagliptin and processes for the preparation thereof. The invention also relates to a pharmaceutical composition comprising therapeutically effective amount of an amorphous form of linagliptin and use of said composition for treatment of diabetes especially type-I or type-II, prediabetes or reduction of glucose tolerance. | 2015-02-19 |
20150051229 | VALOMACICLOVIR POLYMORPHS - The present invention relates to crystalline forms of valomaciclovir, processes for preparing crystalline forms of valomaciclovir, pharmaceutical compositions thereof and methods of using thereof. | 2015-02-19 |
20150051230 | Methods and Compositions for Inhibition of Polymerase - The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents. | 2015-02-19 |
20150051231 | SYNERGISTIC COMBINATIONS OF TRIAZOLES, STROBILURINS AND BENZIMIDAZOLES, USES, FORMULATIONS, PRODUCTION PROCESSES AND APPLICATIONS USING THE SAME - The present invention relates to an agrochemically synergistic formulation of triazoles, strobilurins and benzimidazoles, in specific proportions for controlling and/or combating plagues and diseases caused therefrom in vegetable cultures. Also described are their process of preparation, use and method of use as well as the use of triazoles, strobilurins and benzimidazoles in the preparation of the agrochemically synergistic formulation of the invention. | 2015-02-19 |
20150051232 | USE OF (RS)-S-CYCLOPROPYL-S-(4--5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}PH- ENYL)SULFOXIMIDE FOR TREATING SPECIFIC TUMOURS - The invention relates to the use of (R)—S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide and/or (S)—S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours. | 2015-02-19 |
20150051233 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS - Embodiments of the invention include methods of treating, preventing, and/or reducing the risk of fibrosis in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction of the risk of fibrosis. In at least particular cases, the small molecules are inhibitors of STAT3. | 2015-02-19 |
20150051234 | THERAPY FOR COMPLICATIONS OF DIABETES - A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelia A (ET | 2015-02-19 |
20150051235 | Compositions and Methods for Treating Cardiovascular Diseases - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions. | 2015-02-19 |
20150051236 | Combinations Useful for the Treatment of Chronic Lymphocytic Leukemia - The invention relates to a combination which comprises (a) a DNA damaging agent; and (b) 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidioyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide (“nilotinib”); a pharmaceutical composition comprising such a combination and optionally at least one pharmaceutical acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment chronic lymphocytic leukemia (CLL); the use of such a combination for the preparation of a medicament for the treatment of CLL; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human. | 2015-02-19 |
20150051237 | PYRIDYL-AND PYRIMIDINYL-SUBSTITUTED PYRROLE-, THIOPHENE- AND FURANE-DERIVATIVES AS KINASE INHIBITORS - The present invention provides compounds of the formula (I), or the pharmaceutically acceptable salts thereof, wherein G, W, R | 2015-02-19 |
20150051238 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease. | 2015-02-19 |
20150051239 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS - This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description. | 2015-02-19 |
20150051240 | COMPOSITIONS OF BUPRENORPHINE AND .mu. ANTAGONISTS - The invention relates to a composition comprising buprenorphine and a μ opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; | 2015-02-19 |
20150051242 | RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME - A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mTOR inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such triazole-moiety containing rapamycin analog is in treating renal carcinoma, lung cancer, colon cancer, and breast cancers wherein potency of the drug, its half-life, tissue distribution properties, and its pharmacokinetic properties including bioavailability through oral and intravenous routes are essential to the clinical outcomes. | 2015-02-19 |
20150051244 | ANTIBACTERIAL QUINOLINE DERIVATIVES - The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): | 2015-02-19 |
20150051245 | KINASE PROTEIN BINDING INHIBITORS - The invention relates to protein binding inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer. | 2015-02-19 |
20150051246 | Treatment of Cognitive Impairment with Combination Therapy - Treatment of varying degrees of cognitive impairment associated with Alzheimer's disease with a combination of a phosphodiesterase 4 inhibitor and an acetylcholinestase inhibitor, including roflumilast and donepezil hydrochloride. | 2015-02-19 |
20150051247 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR - Compounds and methods for treating or preventing cancer associated with binding to the urokinase receptor are provided. Biological processes affected by the compounds include cell migration, cell growth, cell adhesion, angiogenesis, cancer cell invasion, apoptosis, tumor formation, tumor progression, metastasis, degradation of the extracellular matrix, pericellular proteolysis, activation of plasminogen, changes in the levels of an extracellular protease, and changes in the levels of a VEGF receptor. | 2015-02-19 |
20150051248 | IMIDAZOLYL METHYL PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS - The present invention is directed to imidazolyl methyl piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved. | 2015-02-19 |
20150051249 | INHIBITION OF MCL-1 AND/OR BFL-1/A1 - This disclosure features compounds and pharmaceutically acceptable salts thereof that inhibit MCL-1 and/or BFL-1/A1 and compositions containing the same. This disclosure also features combinations that include one or more of the MCL-1/BFL-1/A1 inhibitor compounds described herein, or a pharmaceutically acceptable salt thereof; and one or more additional therapeutic agents (e.g., one or more chemotherapeutic agents (including small molecule and/or anti-body based chemotherapy and/or radiation); e.g., one or more therapeutic agents that modulate apoptosis; e.g., one or more therapeutic agents that bind to and inhibit anti-apoptotic proteins or modulate them indirectly; e.g., one or more therapeutic agents that bind to and inhibit, or indirectly modulate, anti-apoptotic BCL-2, BCL-XL, BCL-w, MCL-1, and/or BFL-1/A1; e.g., one or more therapeutic agents that directly bind to and inhibit anti-apoptotic BCL-2/BCL-XL; e.g., agents such as ABT-199, ABT-263 and ABT-737; e.g., ABT-737), or (where applicable) a pharmaceutically acceptable salt of the one or more therapeutic agents (as well as compositions containing the same). Also featured are methods of using such compounds, salts, combinations, and compositions, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., diseased or damaged cells; e.g., insufficient apoptosis of diseased or damaged cells or reduced apoptosis of diseased or damaged cells). | 2015-02-19 |
20150051251 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS - Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided. | 2015-02-19 |
20150051252 | COMPOUNDS FOR USE IN THE TREATMENT OF NEUROBLASTOMA, EWING'S SARCOMA OR RHABDOMYOSARCOMA - The present invention relates to a method of treating cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma comprising administering a therapeutically effective amount of a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof to a subject, preferably a human, in need thereof; to use of the compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for use in the treatment of cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma; and to use of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the treatment of cancer selected from the group consisting of neuroblastoma, Ewing's Sarcoma, or rhabdomyosarcoma. | 2015-02-19 |
20150051253 | ( ) (2R,3S)-2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYRROLIDIN-1-YL-PROPAN-1-ON- E (L)-(+) TARTRATE SALT, ITS METHOD OF PRODUCTION AND USE - The present invention is directed to (−)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (L)-(+)tartrate salt, a pharmaceutical composition comprising said salt, a process for making said salt, and the use of said salt in the treatment of pain. | 2015-02-19 |
20150051254 | Treatment of Cognitive Impairment With PDE4 Inhibitor - This invention relates to the treatment of varying degrees of cognitive impairment associated with, for example, aging, Alzheimer's disease, schizophrenia with low dose administration of a PDE4 inhibitor, specifically roflumilast. | 2015-02-19 |
20150051255 | GLUCOSE TRANSPORTER INHIBITORS - Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound. | 2015-02-19 |
20150051256 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT - The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent. | 2015-02-19 |
20150051257 | SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES - Sulphonamide derivatives of benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted; or 9- or 10-membered bicyclic group, linked to —(O) | 2015-02-19 |
20150051258 | Novel Solid Forms Of Bendamustine Hydrochloride - Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use. | 2015-02-19 |
20150051259 | PRO-INFLAMMATORY MEDIATORS IN DIAGNOSIS AND TREATMENT OF PULMONARY DISEASE - Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease. Various pro-inflammatory mediators are elevated in a model of COPD that can be used predict the presence of COPD and/or subtypes of COPD in human patients. Profiles of these mediators can also predict the responsiveness of some patients to certain therapies, including thromboxane receptor antagonist treatment. Methods are provided for diagnosing a subject as a pulmonary disease candidate that include determining leukocyte expression in the subject of at least one pro-inflammatory mediator and identifying the subject as a pulmonary disease candidate when leukocyte expression in the subject of the pro-inflammatory mediator is increased compared to leukocyte expression of the pro-inflammatory mediator in a healthy individual. The pulmonary disease candidate can also be treated by administering a therapeutically effective amount of a thromboxane receptor antagonist. | 2015-02-19 |
20150051260 | METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS - Compounds, compositions and methods relating to EWS-FLI1 protein inhibitors are provided. The compounds have utility in the treatment of cancers including the Ewing's sarcoma family of tumors. | 2015-02-19 |
20150051261 | Methods of Treating Fatty Liver Disease - The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs. | 2015-02-19 |
20150051262 | NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 2015-02-19 |
20150051263 | IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 2015-02-19 |
20150051264 | INHIBITORS OF NOX4 EXPRESSION AND /OR NOX4 FUNCTION AND THEIR USE IN THE PREVENTION AND TREATMENT OF NERVE INJURY AND/OR NEUROPATHIC PAIN - The present invention relates to modulators, in particular inhibitors, of the expression and/or the function of NADPH Oxidase 4 (Nox4) for use in the prevention and/or treatment of nerve injury, in particular pain, more particularly neuropathic pain. Further disclosed is a method for the identification of Nox4 modulators, a pharmaceutical composition comprising a Nox4 inhibitor and a method for preventing and treating pain, in particular neuropathic pain, in a subject in need of such a treatment. Also, the invention relates to modulators, in particular inhibitors, of the expression and/or the function of NADPH Oxidase 4 (Nox4) for use in the prevention and/or treatment of nerve injury associated with dysmyelination and methods for preventing and treating dysmyelination and diseases associated with dysmyelination. | 2015-02-19 |
20150051265 | Dually Derivatized Chitosan Nanoparticles and Methods of Making and Using the Same - Provided herein is chitosan dually derivatized with arginine and gluconic acid; and methods of making and using the same, e.g., for gene delivery in vivo. | 2015-02-19 |
20150051266 | CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN - The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells. | 2015-02-19 |
20150051267 | BICISTRONIC GENE TRANSFER TOOLS FOR DELIVERY OF miRNAS AND PROTEIN CODING SEQUENCES - Compositions and methods relating to microRNA (miRNA) technology are disclosed. In particular, microRNA (miRNA) expression vectors and methods for the treatment of sensory disorders, e.g., for the treatment of hearing loss, are described. | 2015-02-19 |
20150051268 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT - The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules for their use in improving organ viability and/or longevity. | 2015-02-19 |
20150051269 | Drug Delivery Conjugate Capable of Controlled Release, and Use Thereof - The present invention relates to a hydrophobic drug delivery conjugate, to which cyclodextrin, poly(maleic anhydride), and a hydrophobic drug are bonded, and to a pharmaceutical composition comprising the hydrophobic drug delivery conjugate as an active ingredient. The hydrophobic drug delivery conjugate according to the present invention can effectively control the release rate and the delivery rate of a hydrophobic drug by regulating the physicochemical bonding and/or composition of the cyclodextrin, poly(maleic anhydride), and hydrophobic drug, and can also increase the effect of the drug by significantly increasing the solubility of the hydrophobic drug. Further, the present invention can enable the type of the hydrophobic drug to be varied, as well as a peptide having target directivity to be introduced into a surface of the conjugate, such that the present invention can be applied to the treatment of various diseases in addition to cancer treatment. | 2015-02-19 |
20150051270 | Novel Cyclic Phenoxy Compounds and Improved Treatments for Cardiac and Cardiovascular Disease - A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: | 2015-02-19 |
20150051271 | SELECTIVE ABLATION OF PAIN-SENSING NEURONS BY ADMINISTRATION OF A VANILLOID RECEPTOR AGONIST - The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons. | 2015-02-19 |
20150051272 | Uses of hydroxyl polymethoxylflavones (HPMFs) and derivatives thereof - The invention discloses the uses of hydroxyl polymethoxylflavones and derivative thereof that are relative to inhibit adipogenesis and lower lipid accumulation, wherein the hydroxyl polymethoxylflavones is obtained from the peels of | 2015-02-19 |
20150051273 | USE OF DELPHINIDIN AGAINST STAPHYLOCOCCUS AUREUS - The invention relates to the use of delphinidin or salts thereof, which is aimed at bacteria selected from the group comprising antibiotic-resistant | 2015-02-19 |
20150051274 | SUPPLEMENT COMPOSITION AND METHOD OF USE - The present invention relates to a dietary supplement composition made of: linolenic expeller pressed soybean oil in the range of 65%-85%, Omega 3 (18/12) fish oil 15%-35%, and 1%-20% alpha-tocopherol and a method to use this composition to supplement the diet of a domestic animal, such as a canine or an equine. | 2015-02-19 |
20150051275 | ANTIBACTERIAL AGENTS: SIDECHAINFLUORINATED MYXOPYRONIN DERIVATIVES - The invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R | 2015-02-19 |
20150051276 | FEEDING DETERRENCE IN AGRICULTURAL PESTS SUCH AS HEMIPTERA, LEPIDOPTERA AND COLEOPTERA - Compounds are used as agents that deter feeding of crops by agricultural pests such as hemiptera, lepidoptera and coleoptera, including, but not limited to, stink bugs, codling moth larvae and granary weevils. Feeding deterrence is obtained by contact of the insects with at least one of the compounds of the structure (I) wherein R is —OH, ═O, —OC(O)R | 2015-02-19 |
20150051277 | Compounds from Anisomeles Heyneana - The present invention describes use of compounds of formula 1 or 2 or their compositions for the treatment of leukemia and use of compound of formula 1 or its composition for treatment of infections caused due to | 2015-02-19 |
20150051278 | METHOD OF EXTERMINATING HARMFUL INSECT - The invention is a method of exterminating a harmful insect with an agricultural and horticultural insecticide containing one or more kinds of compound (A) selected from a specific polyoxyethylene fatty acid ester, a specific polyoxyethylene sorbitan fatty acid ester, a specific (poly)glycerol fatty acid ester, and a specific alkyl saccharide, and a compound (B) of an alcohol having a linear or branched alkyl group having 8 to 14 carbon atoms or a linear or branched alkyl ether having 6 to 12 carbon atoms, provided that an agricultural chemical ingredient of an agricultural chemical is not substantially contained. | 2015-02-19 |
20150051279 | STABLE COMPOSITIONS OF THIABENDAZOLE AND IODINE-CONTAINING FUNGICIDES - The present invention relates to stable compositions for the fungicidal equipment of thermoplastic polymers, in particular PVC, comprising thiabendazole, at least one iodine-containing fungicide and at least one epoxide and optionally further fungicidally active compounds, and also to methods for preparing these formulations and to uses thereof for the protection of thermoplastic polymers against attack and destruction by microorganisms. Moreover, the invention relates to mold-resistant PVC materials equipped with the compositions according to the invention. | 2015-02-19 |
20150051280 | Co-Crystals of 3-Iodopropynyl Butylcarbamate - The present invention relates to biocidal agents designed to protect industrial products against microbial, bacterial, fungal and algal infections. In particular, the present invention relates to co-crystals containing 3-iodopropynyl butylcarbamate (IPBC) and to compositions containing said co-crystals which possess improved physical, chemical and workability properties compared with the use of IPBC. | 2015-02-19 |
20150051281 | Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 2015-02-19 |
20150051282 | METHODS OF TREATING A CARDIOVASCULAR DISORDER AND/OR JOINT PAIN IN A SUBJECT ON GLUCOSAMINE THERAPY - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on glucosamine therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2015-02-19 |
20150051283 | COMPOSITION AND METHOD FOR INHIBITION OF PKNG FROM MYCOBACTERIUM TUBERCULOSIS | 2015-02-19 |
20150051284 | Lipid-Lowering Antidiabetic Agent - A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals. | 2015-02-19 |
20150051285 | Alkylamido Compounds and Uses Thereof - Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same. | 2015-02-19 |
20150051286 | ANTHRANILIC ACID DERIVATIVES: NOVEL INHIBITORS OF ADVANCED GLYCATION END-PRODUCTS (AGES) FORMATION - Anthranilic acid derivatives are used to inhibit the formation of advanced glycation end products to reduce complications in diabetes. | 2015-02-19 |
20150051287 | Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 2015-02-19 |
20150051288 | Methods and Compositions for Treatment of Autism - Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder. | 2015-02-19 |
20150051289 | LIQUID FORMULATIONS OF HYPOGLYCAEMIC SULFONAMIDES - The present invention relates to a liquid pharmaceutical formulation of hypoglycaemic sulfonamide, intended for oral or ophthalmic administration. The present invention relates in particular to an oral formulation particularly suitable for paediatric use. | 2015-02-19 |
20150051290 | KINASE INHIBITORS FOR THE TREATMENT OF CANCER - The present invention relates to kinase inhibitors for the treatment of cancer. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of cancer. | 2015-02-19 |
20150051291 | N,N'-DI-1 NAPHTHYLGUANIDINE HCL (NAGH) AND N,N'-DI-P-NITROPHENYLGUANIDINE HCL (NAD) TREATMENT FOR STROKE AT DELAYED TIMEPOINTS - A composition and method of treating stroke by administration of a novel sigma agonist is presented. Twenty-four hours after MCAO, systemic administration of several novel sigma agonists including: Bromo-DTG; Chloro-DTG; N,N′-di-1-Naphthylguanidine hydrochloride (NAGH); N,N′-di-p-Nitrophenylguanidine HCL (NAD) or vehicle were injected subcutaneously daily for 3 days. Rats treated with Bromo-DTG and Chloro-DTG had no significant improvements in any of the motor or cognitive tests while NAGH treated rats showed improved vertical movement and had significantly less motor asymmetry and bias than vehicle treated rats. Sigma receptor agonist NAGH also was found to exert its long-term neuroprotective effects by preserving both gray matter and white matter tracts. Both NAD and NAGH, when administered 24 hours after experimental stroke, reduced neural damage and enhanced behavioral recovery thirty days later which suggests that NAGH and NAD potentially extend the therapeutic window of stroke several fold over the current treatments. | 2015-02-19 |
20150051292 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 2015-02-19 |
20150051293 | PTEROSIN DERIVATIVE-CONTAINING THERAPEUTIC PREPARATION FOR DISEASE ASSOCIATED WITH CARTILAGE LOSS, CARTILAGE DEGENERATION AND/OR CARTILAGE THINNING - An object of the present invention is to provide a therapeutic preparation and method for diseases associated with cartilage loss, cartilage degeneration and/or cartilage thinning. The present invention provides a therapeutic preparation comprising a pterosin derivative or a pharmaceutically acceptable salt thereof for diseases associated with cartilage loss, cartilage degeneration and/or cartilage thinning; and a therapeutic method for the diseases. | 2015-02-19 |
20150051294 | Myricanol Derivatives and Uses Thereof for Treatment of Neurodegenerative Diseases - The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. | 2015-02-19 |
20150051295 | USE OF PROPANOL AND PROPENOL DERIVATIVES AS ANTIOXIDANTS - The invention relates to the use of propanol and propenol derivatives as antioxidants, to compositions comprising propanol and propenol derivatives and the preparation thereof, and to certain propanol and propenol derivatives and the preparation thereof. | 2015-02-19 |